Eine Studie zur Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und Wirksamkeit von RO7034067 bei spinaler Muskelatrophie (SMA) vom Typ 2 und 3 (SUNFISH)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH)

  • Erkrankung der Muskeln und peripheren Nerven
  • Spinale Muskelatrophie (SMA)
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:

Abgeschlossen

Diese Studie läuft in
Stadt
  • Freiburg im Breisgau
Studien-ID:

NCT02908685 2016-000750-35 BP39055

      Studienzentren finden

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden für Laien bearbeitet.

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden nicht geändert.

      Results Disclaimer

      Studienzusammenfassung

      Multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Risdiplam in adult and pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an exploratory dose finding part (Part 1) of Risdiplam for 12 weeks and a confirmatory part (Part 2) of Risdiplam for 24 months.

      Hoffmann-La Roche Sponsor
      Phase 2 Phase
      NCT02908685, BP39055, 2016-000750-35 Studien-ID
      Placebo, RO7034067 Treatments
      Muscular Atrophy, Spinal Condition
      Official Title

      A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy Patients

      Einschlusskriterien

      All Gender
      ≥ 2 Years & ≤ 25 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Confirmed diagnosis of 5q-autosomal recessive SMA
      • Negative blood pregnancy test at screening and agreement to comply with measures to prevent pregnancy and restrictions on sperm donation
      • For Part 1: Type 2 or 3 SMA ambulant or non-ambulant
      • For Part 2: 1) Type 2 or 3 SMA non-ambulant; 2) RULM entry item A greater than or equal to 2; 3) ability to sit independently as assessed by item 9 of the MFM
      Exclusion Criteria
      • Concomitant or previous participation in any investigational drug or device study within 90 days prior to screening, or 5 half-lives of the drug, whichever is longer
      • Concomitant or previous administration of a SMN2-targeting antisense oligonucleotide, SMN2 splicing modifier or gene therapy either in a clinical study or as part of medical care
      • Any history of cell therapy
      • Hospitalization for a pulmonary event within the last 2 months or planned at time of screening
      • Surgery for scoliosis or hip fixation in the one year preceding screening or planned within the next 18 months
      • Unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system diseases as considered to be clinically significant by the Investigator
      • Presence of clinically significant electrocardiogram abnormalities before study drug administration from average of triplicate measurement or cardiovascular disease indicating a safety risk for participants as determined by the Investigator
      • Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first dose administration
      • Recently initiated treatment (within less than [<] 6 months prior to randomization) with oral salbutamol or another beta 2-adrenergic agonist taken orally
      • Any prior use of chloroquine, hydroxychloroquine, retigabin, vigabatrin or thioridazine, is not allowed
      • Ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to Risdiplam or to the constituents of its formulation
      • Recent history (less than one year) of ophthalmological diseases
      • Participants requiring invasive ventilation or tracheostomy

      Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de

       

      Über klinische Studien

      Erfahren Sie mehr über klinische Studien und wie sie durchgeführt werden

      Erfahren Sie mehr